- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
With the advent of targeted drug therapy for treating cancer, it has become clear that an important predictor of success of these therapies is whether such a drug is reaching its target in the patient. The bottom-line measure of success is survival, but having some rapid measure of drug targeting would enable oncologists to make early changes in therapy if the amount of drug reaching its intended target was insufficient to kill a tumor.
Ralph Weissleder and his colleagues at the Harvard Medical School may have developed just what oncologists ordered. Using magnetic nanoparticles as a sensitive readout of drug targeting, and a miniaturized nuclear magnetic resonance (NMR) instrument, Weissleder's team created a novel system for directly measuring both target expression and drug binding in a small number of tumor cells obtained via needle biopsy. This new technique has the potential to provide real-time results at the time of biopsy. Weissleder is the co-principal investigator of the MIT-Harvard Center for Cancer Nanotechnology Excellence.
Reporting its work in the journal ACS Nano, the Harvard team showed that they could use their system to measure how effective so-called PARP inhibitors are at binding to their intended target, the protein poly(ADP-ribose) polymerase (PARP). Several PARP inhibitors are moving through clinical trials for the treatment of breast and ovarian cancers. The researchers note, though, that their system is broadly applicable to most any type of drug that must bind to a specific molecular target.
The key component of this specific assay system is a dextran-coated, cross-linked iron oxide (CLIO) nanoparticle linked to a small molecule inhibitor of PARP. Once the investigators prepared this construct, they tested it on five different tumor cell lines that produce varying levels of PARP. After mixing the nanoparticles with the cells, levels of PARP expression were measured using a miniaturized NMR instrument about the size of a cell phone. The results, obtained from as few as 1500 cells, matched those obtained using standard protein expression technologies.
Next, the investigators tested their system to see if it could determine target binding for five different commercially available PARP inhibitors. Again, the results, obtained in less than 90 minutes and from 10,000 cells, matched those obtained using other, more elaborate, time-consuming, and far less sensitive standard technologies.
With these results in hand, Weissleder's team measured drug targeting in live cells and blood samples. From samples as small as 1500 cells, the investigators found that their system could detect differences in PARP expression and drug binding across different tumor types. The results, wrote the researchers, "suggest the potential for a future 'treatment index,' where patients with high drug-binding efficacy would receive lower therapeutic doses, while patients with low drug-binding efficacy would require higher doses or be candidates to receive alternative drugs." The investigators are already at work on a second-generation system that would require even fewer, or even single, cells that might enable clinicians to identify the development of rare drug resistant cells.
About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Ultrasensitive sensor using N-doped graphene July 26th, 2016